◀ Back to ERBB2

ERBB2 — HDAC1

Text-mined interactions from Literome

Scott et al., Mol Cancer Ther 2002 (Breast Neoplasms) : Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter reporting cell screen
Drummond et al., Clin Cancer Res 2005 (Neoplasms, Experimental) : ErbB2 overexpressing human cancers represent potentially sensitive targets for therapy by candidate histone deacetylase (HDAC) inhibitors as we have shown that HDAC inhibitors can selectively reduce ErbB2 expression by repressing the ErbB2 promoter and accelerating the decay of cytoplasmic ErbB2 transcripts